CACNA1E Variants Affect Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 3 by Trombetta, Maddalena et al.
CACNA1E Variants Affect Beta Cell Function in Patients
with Newly Diagnosed Type 2 Diabetes. The Verona
Newly Diagnosed Type 2 Diabetes Study (VNDS) 3
Maddalena Trombetta
1,2., Sara Bonetti
1*
., MariaLinda Boselli
1, Fabiola Turrini
1, Giovanni Malerba
3,
Elisabetta Trabetti
3, PierFranco Pignatti
3, Enzo Bonora
1,2, Riccardo C. Bonadonna
1,2*
1Department of Medicine, University of Verona, Verona, Italy, 2Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy, 3Department of Life and
Reproduction Sciences, University of Verona, Verona, Italy
Abstract
Background: Genetic variability of the major subunit (CACNA1E) of the voltage-dependent Ca
2+ channel CaV2.3 is associated
to risk of type 2 diabetes, insulin resistance and impaired insulin secretion in nondiabetic subjects. The aim of the study was
to test whether CACNA1E common variability affects beta cell function and/or insulin sensitivity in patients with newly
diagnosed type 2 diabetes.
Methodology/Principal Findings: In 595 GAD-negative, drug naı ¨ve patients (mean6SD; age: 58.5610.2 yrs; BMI:
29.965 kg/m
2, HbA1c: 7.061.3) with newly diagnosed type 2 diabetes we: 1. genotyped 10 tag SNPs in CACNA1E region
reportedly covering ,93% of CACNA1E common variability: rs558994, rs679931, rs2184945, rs10797728, rs3905011,
rs12071300, rs175338, rs3753737, rs2253388 and rs4652679; 2. assessed clinical phenotypes, insulin sensitivity by the
euglycemic insulin clamp and beta cell function by state-of-art modelling of glucose/C-peptide curves during OGTT. Five
CACNA1E tag SNPs (rs10797728, rs175338, rs2184945, rs3905011 and rs4652679) were associated with specific aspects of
beta cell function (p,0.0520.01). Both major alleles of rs2184945 and rs3905011 were each (p,0.01 and p,0.005,
respectively) associated to reduced proportional control with a demonstrable additive effect (p,0.005). In contrast, only the
major allele of rs2253388 was related weakly to more severe insulin resistance (p,0.05).
Conclusions/Significance: In patients with newly diagnosed type 2 diabetes CACNA1E common variability is strongly
associated to beta cell function. Genotyping CACNA1E might be of help to infer the beta cell functional phenotype and to
select a personalized treatment.
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Introduction
CaV2.3 is one non–L-type high-voltage-activated (HVA)
channel belonging to the voltage-gated Ca
2+ channel family,
whose members mediate Ca
2+ entry into cells in response to
membrane depolarization [1].
CaV2.3, which is expressed primarily in neuronal cells [2] and
in pancreatic beta cells [1], plays a key role in second-phase insulin
release [3]. Silencing CaV2.3 expression in INS-1 cells blunts
glucose-stimulated insulin secretion [4]. CaV2.3
2/2 mice display
fasting hyperglycemia and impaired glucose tolerance [5,6].
CaV2.3 is composed of a major pore-forming alpha 1 E subunit
(CACNA1E), which determines most of the channel’s properties, and
of multiple auxiliary subunits (alpha 2, beta, delta, gamma) [1].
Two earlier studies, performed in two different ethnic groups,
reported that CACNA1E variants are associated to type 2 diabetes
risk [7,8]. However, their findings differed because in one study
the metabolic phenotype associated to CACNA1E variability was
insulin secretion [8], in the other study it was insulin sensitivity [7].
Both studies used insulin concentrations after a secretory stimulus
to explore beta cell function. However, insulin levels are
determined by both beta cell function and insulin clearance,
which is in turn influenced by insulin sensitivity. Thus, any insulin
based assessment of beta cell function also reflects insulin
clearance. Indeed, in the former study [8], the association between
CACNA1E variability and beta cell function was sought using
either surrogate indexes of glucose-induced insulin secretion
during OGTTs, or insulin levels in the late part of IVGTTs. In
the latter study [7], only acute insulin response after i.v. glucose
challenge was measured, i.e. a facet of beta cell function in which
CaV2.3 should play a nonsignificant role [3]. Finally, in both
studies, associations between CACNA1E variability and metabolic
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hypothesized that, if common CACNA1E variability were relevant
in determining beta cell function, this might be evident also when
overt diabetes ensues and such an information would be of
potential clinical interest.
We therefore undertook the present study to test whether the
genetic variability of CACNA1E affects key metabolic phenotypes
(beta cell function and insulin sensitivity, both assessed by state-of-
art methods) in patients with newly diagnosed type 2 diabetes.
The CACNA1E region was tested by genotyping a number of tag
SNPs, selected to capture most (,93%) of common CACNA1E
variability. We used the database of the Verona Newly Diagnosed
Type 2 Diabetes Study (VNDS), a cohort in which associations
between common genetic variants and metabolic phenotypes have
already been shown to be detectable [9,10], possibly because of the
absence of the potentially confounding effects of long-lasting
antidiabetic treatments and of the limited impact of duration and
severity of hyperglycemia per se on the glucose insulin homeostatic
system
Methods
Verona Newly Diagnosed Type 2 Diabetes Study (VNDS)
The VNDS is an ongoing study aiming at building a biobank of
patients with newly diagnosed type 2 diabetes [9,10]. A detailed
description of the study population and of the experimental design
is found online. In this study we report the data collected in 595
patients, whose characteristics are summarized in Table 1. Each
subject gave informed written consent before participating in the
research, which was approved by the Human Investigation
Committee of the Verona City Hospital.
Standard clinical parameters were assessed in all patients.
Metabolic tests were carried out on two separate days in random
order.OnonedayanOGTT(75 g)wasperformedtoassessbetacell
function, as previously described [11]. On a separate day, a eugly-
cemic insulin clamp was performed to assess insulin sensitivity [9]
Analytical procedures
Plasma glucose concentration was measured in duplicate with a
Beckman Glucose Analyzer II (Beckman Instruments, Fullerton,
CA, USA) or a YSI 2300 Stat Plus Glucose&Lactate Analyzer
(YSI Inc., Yellow Springs, OH, USA), at bedside. Serum C-
peptide and insulin concentrations were measured by chemilumi-
nescence as previously described [12]. Glycated hemoglobin and
serum lipids were measured by standard in-house methods. GAD-
antibodies were measured by immunoradiometry (CentAK,
Medipan, Germany), according to manufacturer’s instructions.
Calculations
The amount of glucose metabolized during the last 60 min of
the clamp (M value, reference insulin sensitivity) was computed
with standard formulae [13,14].
The following classical indexes of beta cell function were
computed [15]:
N Insulinogenic Index: (Insulin3092Insulin09)/(Glucose3092Glu-
cose09), units: mU/mmol;
N Corrected Insulin Response1209 (CIR1209): Insulin1209/[Gluco-
se1209*(Glucose120923.89)] [15]; units: mU*L/mmol
2.
Further insights in beta cell function were sought by
mathematical modeling (see below and Supporting Information
S1 Tables S1, S2).
Modeling of Beta Cell Function
The analysis of the glucose and C-peptide curves during the
OGTTs of the VNDS was performed as described in previous
publications [9,10] and builds upon previous works from other
laboratories [16,17]. Insulin secretion rate is described as the sum
of two components, one responding to the rate of increase of
glucose, the other to glucose concentration itself. Modeling details
are found online in the Supporting Information S1.
There are two main physiological outputs of the model:
Table 1. Clinical and metabolic features of the VNDS population.
Variable Males Females All
Number (M/F) 409 186 595
Age (yrs) 59 [51–65] 61 [56–67] 60 [52–66]
BMI (kg/m2) 28.7 [26.1–32.1] 30.4 [27.2–34.1] 29.3 [26.4–32.9]
Waist (cm) 102 [94–111] 97 [90–103] 100 [93–108]
Fasting P-glucose (mmol/l) 7 [6.2–8.0] 7.2 [6.2–8.1] 7.1 [6.2–8.0]
2hr P-glucose (mmol/l) 13.1 [10.8–16.2] 12.9 [10.1–16.3] 13.1 [10.6–16.2]
HbA1c (%) 6.7 [6.1–7.5] 6.6 [6.2–7.4] 6.6 [6.1–7.5]
Triglycerides (mmol/l) 1.5 [1.0–2.1] 1.3 [1.0–2.0] 1.4 [1.0–2.0]
HDL-cholesterol (mmol/l) 1.1 [0.95–1.3] 1.2 [1.0–1.4] 1.1 [1.0–1.3]
Cholesterol (mmol/l) 4.8 [4.2–5.5] 5.1 [4.5–5.8] 5.0 [4.3–5.6]
SBP (mmHg) 134 [120–146] 140 [130–150] 136 [122–150]
DBP (mmHg) 80 [80–90] 85 [80–90] 82 [80–90]
Insulin Sensitivity (mmol/min/m2 BSA) 602 [365–885] 596 [408–796] 599 [384–856]
Insulinogenic Index (mU/mmol) 3.6 [2.0–5.9] 4.8 [2.5–8.2] 3.9 [2.1–6.9]
CIR1209 (mUxL/mmol2) 0.4 [0.2–1.1] 0.6 [0.3–1.4] 0.5 [0.2–1.3]
Data are presented as median [I.Q. range].
doi:10.1371/journal.pone.0032755.t001
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22 BSA] ? [mmol?l
21?min
21]
21 of
beta cell function: it is presented as the amount of insulin
secreted in response to a rate of glucose increase of 1 mmol/l
per min which lasts for 1 minute;
2. proportional control of beta cell function: it is presented as the
stimulus-response curve linking glucose concentration (x axis)
to insulin secretion rate (ISR [pmol?min
21?m
22 BSA]; y axis)
at the pre-selected glucose concentrations of 5.5, 8.0, 11.0, 15.0
and 20.0 mmol/l.
Genotyping
A peripheral blood sample was collected from each patient and
the DNA was extracted by standard salting out method.
Ten tag-SNPs (rs558994, rs679931, rs2184945, rs10797728,
rs3905011, rs12071300, rs175338, rs3753737, rs2253388 and
rs4652679), which capture ,93% of the common genetic
variability of this genomic region (about 320 kbp) (fig. 1), were
selected with the software GEVALT (GEnotype Visualization and
ALgorithmic Tool) [18]. The LD values in our population,
expressed as r
2, are consistent with the values reported by
HapMap (fig. 1).
Genotypes were assessed by the high-throughput genotyping
Veracode technique (Illumina Inc, CA), applying the GoldenGate
Genotyping Assay according to manufacturer’s instructions [19].
Statistical Analysis
Data are presented as medians and interquartile range, unless
otherwise indicated. Hardy-Weinberg equilibrium was tested by
chi-square test. Before comparisons, skewed variables were log-
transformed to improve the approximation to the Gaussian
distribution. Single variant association analyses were carried out
by generalized linear models (GLM) as implemented in SPSS and
they were adjusted for a number of potential confounders,
including age, gender and BMI. Since the logarithmic transfor-
mation was insufficient to improve the distribution of the
derivative control of beta cell function, the latter was first analyzed
by Kruskal-Wallis test. All statistical analyses were carried out with
the SPSS 12.0 software. Statistical significance was declared at
p,0.05.
Results
Clinical Features of the Study Population
Anthropometric, clinical and metabolic features of the study
subjects are shown in table 1. Further details can be found in the
Supporting Information S1.
Effects of CACNA1E variants on clinical and metabolic
parameters
Allele distribution was compatible with the Hardy-Weinberg
equilibrium in all 10 SNPs (p.0.16 or more).
Anthropometric, clinical and metabolic features of the study
subjects, layered according to rs558994, rs679931, rs2184945,
rs10797728, rs3905011, rs12071300, rs175338, rs3753737,
rs2253388 and rs4652679 alleles, are found in the online material
(Supporting Information S1 Tables from S3 to S12).
Figure 1. Gene structure, location of polymorphic sites, and pairwise LD among SNPs in CACNA1E. The upper portion of the figure shows
the gene structure and location of the polymorphisms genotyped in the VNDS population. The lower portion of the figure shows a schematic of the
pairwise LD, calculated as r
2, among the SNPs in the VNDS patients. The dotted lines connect each SNP name and position with the corresponding
cell in the LD matrix. Increasing level of LD is shown by darker grayscale.
doi:10.1371/journal.pone.0032755.g001
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proportional control of beta cell function
Both major alleles of rs10797728 (A) and rs175338 (G), which
are in modest linkage disequilibrium with each other (D9: 0.9,
r
2: 0.43) (fig. 1), were associated to a significant impairment in
the derivative control of beta cell function, i.e. the response of beta
cell to the rate of glucose increase (p=0.01 and p=0.03
respectively by Kruskal-Wallis) (Table 2). The major allele of
rs10797728 was also associated to lower basal insulin secretion
rate (20.0760.03 log units, p,0.03) (Supporting Information S1
Table S6).
Patients carrying the major alleles A of rs2184945, under a
dominant model, (Supporting Information S2 Fig. S1a) or G of
rs3905011 (Supporting Information S2 Fig. S1b) had defective
proportional control of beta cell function, i.e. the curve relating
glucose (stimulus) to insulin secretion rate (response) (p,0.01 and
p,0.005 respectively by ANOVA). The effects of rs2184945 and
rs3905011 genotypes on the beta cell response to glucose
concentration were statistically independent of each other
(p,0.02 and p,0.01, respectively, in a multivariate model
including both SNPs), consistently with their low degree of linkage
disequilibrium (D9: 0.26, r
2: 0.06).
We then computed a CACNA1E score in order to investigate the
combined effect of rs2184945 and rs3905011 on the proportional
control, by assigning a score of 1 to all carriers of the rs2184945 A
allele, irrespectively of zygosity, and a score of 1 for each
rs3905011 G allele. Hence, the CACNA1E score could range from
a minimum of 0 (rs2184945 TT–rs3905011 AA genotype) to a
maximum of 3 (genotype rs2184945 AA or AT–rs3905011 GG
genotype) (Supporting Information S1 Table S13). The higher was
the CACNA1E score, the lower was the insulin secretion rate in
response to glucose concentration (Fig. 2) (p,0.005).
Finally, the major G allele of rs4652679 was associated to
significantly lower basal insulin secretion rate (20.0660.03 log
units, p,0.04) and to significantly more efficient insulin clearance
(+0.0760.02 log units, p,0.01) (Supporting Information S1 Table
S12).
Effects of CACNA1E variants on surrogate indexes of beta
cell function
The above results were mirrored by significantly lower CIR120,
a surrogate index of beta cell function, both in carriers of either
rs2184945 A allele or rs3905011 G allele and in carriers of
progressively higher CACNA1E score (+0.2360.06 log units,
p,0.001, data not shown).
Furthermore, lower fasting and 2-hour insulin levels were
associated to the rs3905011 G allele (Supporting Information S1
Table S7). In the latter case, statistical significance stayed the
same, even after adjusting for basal insulin secretion and clamp-
measured insulin clearance (Supporting Information S1 Table S7).
Effect of CACNA1E variants on insulin sensitivity and
indicators of glucose control
The minor A allele of rs2253388 was associated to more severe
insulin resistance, according to a recessive model (+0.0860.04 log
units p,0.05) (Supporting Information S1 Table S11). This
association stayed statistically significant after adjusting for age,
gender and BMI.
In parallel to their influence on beta cell function, the rs2184945
A allele and the rs3905011 G allele were associated to higher 2-
hour plasma glucose (both SNPs) and to worse fasting plasma
glucose and HbA1c (rs3905011 G) (Supporting Information S1
Tables S5 and S7).
Further associations of CACNA1E variability with other clinical
metabolic parameters are reported and discussed in the Support-
ing Information S1.
Discussion
This study explored the potential role(s) of ten CACNA1E
variants (fig. 1), purposely selected to capture ,93% of common
CACNA1E variability, in determining pathophysiological pheno-
types (i.e. beta cell function and insulin sensitivity) in patients with
newly diagnosed type 2 diabetes of the VNDS. We also genotyped
rs679931 and rs3753737 because of their previously reported role
in type 2 diabetes risk and in beta cell function regulation [7,8].
The interesting and novel feature of our study is the use of state-
of-art methods [16,17,20,21], instead of surrogate markers, to
assess beta cell function and insulin sensitivity in a sample of
patients with newly diagnosed type 2 diabetes. This population is
presumably not yet influenced by long-standing hyperglycemia
and/or pharmacological antidiabetic treatment, which could
modify phenotype-genotype interaction.
Our data show that up to five (rs10797728, rs175338,
rs2184945, rs3905011 and rs4652679) out of ten CACNA1E SNPs
may exert some influence on different components of beta cell
function (derivative control and proportional control), which in
some (rs2184945 and rs3905011 genotypes), but not all cases, are
also reflected by changes in glucose control (Supporting Informa-
tion S1 Tables S5 and S7).
The apparent influence exerted by rs10797728 and 175338 on
the derivative control of beta cell function (table 2) is somewhat
surprising, in the light of the claim that CaV2.3 is involved in the
regulation of only second phase insulin secretion [3] and that the
derivative control of beta cell function describes first phase insulin
secretion in response to intravenous glucose challenges [11,20,21].
This apparent lack of biological plausibility may indicate that this
is simply a chance finding. However, at a close inspection, the data
reported by Jing et al., possibly the most thorough study on the
relationship between CaV2.3 activity and beta cell function, do
show a trend also for reduced first phase insulin secretion in
perfused pancreata from CaV2.3
2/2 mice [3]. Thus, if replicated
Table 2. Derivative control of beta cell function in patients of
the VNDS according to genotype of CACNA1E variants.
CACNA1E
SNP n AA AB BB
p value
(k-w)
rs558994 514 653.6647.6 609.9640.4 568.26105.3 0.69
rs679931 515 700.1650.9 578.2642.3 7126125.4 0.11
rs2184945 521 707.1654.6 585.5646.7 683.1671.2 0.04
rs10797728 523 658642.1 558647.5 10156209.8 0.01
rs3905011 521 580.5646.3 646.9646.2 734.7696.4 0.59
rs12071300 529 642.9638 587657.4 962.56205.1 0.07
rs175338 507 658.8641.5 570.3649.1 1054.36218.7 0.03
rs3753737 512 636.1642.4 656.6655 620.8694.2 0.91
rs2253388 515 619.5643.7 641.2651.4 7546111.1 0.32
rs4652679 518 629.2642.7 636.5647.9 598.66118.7 0.85
Data are presented as mean6SE. A non-parametric test has been performed
(Kruskal-Wallis) since the variable was not normally distributed.
A=major allele; B=minor allele.
doi:10.1371/journal.pone.0032755.t002
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relevance in patients with newly diagnosed type 2 diabetes.
Both rs2184945 and rs3905011 genotypes exerted a strong,
independent influence on the proportional control of beta cell
function (Supporting Information S2 fig. S1a and fig. S1b,
respectively). Furthermore, our finding that homozygous carriers
of ‘‘poor’’ beta cell function alleles at both SNPs had a ,30%
reduction in the insulin secretory response to glucose, compares
well with the 20–30% reduction of second phase insulin secretion
reported in perfused pancreata from CaV2.3
2/2 mice [3]. It is
noteworthy that the p value of the CACNA1E score was virtually
unaffected (p=0.001) by the inclusion in a multivariate model also
of the genetic variants previously reported by us to be associated to
beta cell function in the VNDS (rs7901695 or rs7903146 in
TCF7L2 and rs6717980 or rs2384628 in GCKR) [9,10]. Further-
more, the associations of these two SNPs with indicators of glucose
control, such as plasma glucose and HbA1c, are consistent with a
potentially relevant role in glucose homeostasis of patients with
newly diagnosed type 2 diabetes (Supporting Information S1
Tables S5 and S7).
In the present study, we did not genotype the +8130A/G
variant (rs41315711) of CACNA1E, previously reported to be
associated to diabetes risk and insulin resistance in Pima Indians
[7], or any variant in linkage disequilibrium with it. This
prevented us from replicating in the VNDS its association with
insulin sensitivity. Nevertheless, the admittedly weak association of
the rs225338 A allele with worse insulin resistance we report in our
study (Supporting Information S1 Table S11) may reinforce the
rationale to investigate more thoroughly the relationship of this
gene, or of a closely related region, with the mechanisms
modulating insulin sensitivity. Since, according to the present
body of knowledge, CaV2.3 plays direct pathophysiological roles in
the beta cell [3,6], the relationship of its genetic variability to
insulin resistance, if not spurious, has to be an indirect one.
Our findings may have two further implications. First, as already
shown by us for TCF7L2 [9] and GCKR [10], a role of CACNA1E in
determiningbeta cell functioncanbe detected also inovertdiabetes.
Thus, recognizing and assessing genetic heterogeneity in patients
with type 2 diabetes might turn out to be valuable in outlining a
‘‘metabolic’’ prognosis. Second, different genomic regions of the
candidate gene CACNA1E are involved in regulating different
components of beta cell function, suggesting that this genomic area,
or genomic areas closely related to it, may play a relevant role in
regulating both basal and glucose induced insulin secretion.
There are a number of limitations in our study. i- This is not a
population based study, although we found that VNDS subjects
are fairly representative of Italian patients with type 2 diabetes,
comparing of their features with previously published studies [22].
However, in our cohort there is a higher than expected prevalence
of the male gender, possibly reflecting a gender related referral
bias. ii. The size of our cohort is not very large, although the direct
assessment of the phenotypes of interest, instead of using surrogate
indexes, may partially compensate for it. iii- We did not explore
many important pathophysiological phenotypes, e.g. incretin role
and liver vs peripheral insulin resistance, which are not measured
by the state-of-art methods that we used to assess beta cell function
and insulin sensitivity [16,17,20,21]. iv- Our findings need to be
replicated in an independent sample of patients, as in all association
Figure 2. Effects of CACNA1E score on the curve relating insulin secretion rate (y axis) to glucose concentration (x axis), i.e. the
proportional control of beta cell function, in patients with newly diagnosed type 2 diabetes of the VNDS. The CACNA1E score was
computed by considering two levels for rs2184945 (TT and AA/AT) and 3 levels for rs3905011 (AA, GA and GG) and by scoring them from 0 to 1 or 2
respectively. The CACNA1E score could range from a minimum of 0 (double genotype rs2184945TT–rs3905011AA) to a maximum of 3 (a rs2184945AA/
AT–rs3905011GG genotype) (Supporting Information S1 Table S13). The higher was the CACNA1E score, the lower was the beta cell insulin secretory
response to glucose (p,0.005 after adjusting for age, gender and BMI). Data are presented as mean6SEM.
doi:10.1371/journal.pone.0032755.g002
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of beta cell function and insulin sensitivity in large samples requires
time and considerable resources. Indeed, to the best of our
knowledge, there is no other large cohort of European patients with
type 2 diabetes who underwent the same kind of metabolic
phenotyping. v- Our study was performed in Italian patients;
extrapolations to other ethnic groups should be made with caution.
In summary, we have reported that common CACNA1E
variation is significantly related to beta cell function in patients
with newly diagnosed type 2 diabetes. Hence, we speculate that
CACNA1E genotype might be a useful tool to refine diagnosis and
prognosis of patients with type 2 diabetes.
Supporting Information
Supporting Information S1 Includes text with supplemental
information regarding methods and results, and tables from S1 to
S13.
(DOC)
Supporting Information S2 Includes supplemental figures S1a
and S1b.
(DOC)
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